Beauty brands are racing to market a new "GLP-1 skincare" category as dermatologists and surgeons report a rise in patients worried about facial changes linked to weight‑loss drugs such as Ozempic, Wegovy and Mounjaro. The products aim to address so‑called "Ozempic face" — a constellation of sagging cheeks, sunken under‑eyes and loosened jawlines that has become a growing concern as GLP‑1 medications are prescribed more widely for type 2 diabetes and obesity.
GLP‑1 agonists work by slowing stomach emptying and suppressing appetite, which prolongs feelings of fullness and accelerates weight loss. That rapid reduction in facial fat and overall body volume can outpace the skin’s ability to recoil, leaving a hollowed or aged appearance. "This happens due to rapid fat loss in the face. When fat is lost too fast, there isn’t enough time for the skin to tighten back," said Dr Chandani Jain Gupta, a dermatologist at Elantis Healthcare in New Delhi.
The cosmetic fallout of the drug surge is now being seen in clinics. The American Academy of Facial Plastic and Reconstructive Surgery has reported that 60 percent of facial plastic surgeons are seeing an increase in patients presenting with what has been dubbed "Ozempic Face." Clinicians say the problem is compounded when appetite suppression also reduces fluid and nutrient intake, leaving skin drier and less resilient in addition to losing subcutaneous volume.
Beauty companies are responding with topical serums and creams positioned specifically for GLP‑1 users, promoting improved hydration and anti‑ageing benefits. Dermatologists urge caution about expectations. "Topical creams cannot replace fat loss or miraculously tighten the skin," said Dr Nidhi Rohatgi, consultant dermatologist at Max Hospital, Panchsheel Park. While moisturisers and active ingredients can improve skin quality and hydration, she said, structural loss often requires more invasive measures such as fat grafting or injectable treatments to restore facial volume.
Clinicians recommend practical, non‑procedural steps to mitigate skin changes while on GLP‑1 therapy: lose weight gradually rather than rapidly, maintain adequate protein intake, stay well hydrated, and ensure sufficient micronutrients that support skin health. "To protect skin during weight‑loss, we ensure that protein intake is good along with supplementation for the required nutrients such as Omega‑3 and good moisturisation to support skin health," said Dr Kiran Sethi, a New Delhi dermatologist and author. Vitamin C, zinc and healthy fats were singled out as important for maintaining elasticity and skin repair.
The emergence of "GLP‑1 skincare" has prompted debate about whether the category represents genuine scientific innovation or savvy repositioning of existing cosmetic approaches to capitalise on a headline issue. Experts say the products can play a supportive role in skincare routines but are not a substitute for volume restoration when rapid facial fat loss has occurred. For patients starting GLP‑1 drugs, clinicians advise discussion with both prescribing physicians and dermatologists to plan nutrition, hydration and realistic expectations — and to consider referral to facial plastic specialists if concerns about long‑term structural change arise.